Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis

Ibrexafungerp (formerly SCY-078) is a semisynthetic triterpenoid and potent (1→3)-β-d-glucan synthase inhibitor. We investigated the in vitro activity, pharmacokinetics, and in vivo efficacy of ibrexafungerp (SCY) alone and in combination with antimold triazole isavuconazole (ISA) against invasive p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Petraitis, Vidmantas, Petraitiene, Ruta, Katragkou, Aspasia, Maung, Bo Bo Win, Naing, Ethan, Kavaliauskas, Povilas, Barat, Stephen, Borroto-Esoda, Katyna, Azie, Nkechi, Angulo, David, Walsh, Thomas J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2020
Assuntos:
Experimental Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7269506/
https://ncbi.nlm.nih.gov/pubmed/32179521
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02429-19
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados